EXEL vs JAZZ
Exelixis, Inc. and Jazz Pharmaceuticals plc, both Healthcare
Jazz Pharmaceuticals plc is the larger company at $14B against $13B. Over the past year JAZZ returned +123% against +50% for EXEL. Ryufin's sector-relative Smart Score puts EXEL ahead, 8/10 against 6/10.
| Figure | EXEL | JAZZ |
|---|---|---|
| Last close | $56.07 | $249 |
| Market cap | $13B | $14B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.6 | n/a |
| 1-year return | +50% | +123% |
| 5-year return | +225% | +46% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 6/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Exelixis, Inc.
Revenue of $611M in Q1 2026, net income $210M. Its largest reported line is Product Gross, 87% of the disclosed total.
Jazz Pharmaceuticals plc
Revenue of $1.1B in Q1 2026, net income $293M. Its largest reported line is Oncology, 31% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.